Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
复制标题
DOI:
10.1016/j.cell.2021.03.029
复制
发表时间:
2021-04-29
期刊:
影响因子:
64.5
通讯作者:
Crowe JE Jr
中科院分区:
文献类型:
--
作者:
Suryadevara N;Shrihari S;Gilchuk P;VanBlargan LA;Binshtein E;Zost SJ;Nargi RS;Sutton RE;Winkler ES;Chen EC;Fouch ME;Davidson E;Doranz BJ;Chen RE;Shi PY;Carnahan RH;Thackray LB;Diamond MS;Crowe JE Jr
Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike (S) protein receptor-binding domain and block virus interactions with the cellular receptor angiotensin-converting enzyme 2. We describe a panel of human mAbs binding to diverse epitopes on the N-terminal domain (NTD) of S protein from SARS-CoV-2 convalescent donors and found a minority of these possessed neutralizing activity. Two mAbs (COV2-2676 and COV2-2489) inhibited infection of authentic SARS-CoV-2 and recombinant VSV/SARS-CoV-2 viruses. We mapped their binding epitopes by alanine-scanning mutagenesis and selection of functional SARS-CoV-2 S neutralization escape variants. Mechanistic studies showed that these antibodies neutralize in part by inhibiting a post-attachment step in the infection cycle. COV2-2676 and COV2-2489 offered protection either as prophylaxis or therapy, and Fc effector functions were required for optimal protection. Thus, natural infection induces a subset of potent NTD-specific mAbs that leverage neutralizing and Fc-mediated activities to protect against SARS-CoV-2 infection using multiple functional attributes. Suryadevara et al. find human neutralizing antibodies to the spike protein N-terminal domain that arise from natural infection with SARS-CoV-2. These antibodies inhibit post-attachment steps of the viral cycle and initiate protective immune responses via the antibody Fc domain.
登录
查看更多内容
DOI:
10.1056/nejmoa2029849
发表时间:
2021-01-21
期刊:
The New England journal of medicine
影响因子:
--
作者:
Chen P;Nirula A;Heller B;Gottlieb RL;Boscia J;Morris J;Huhn G;Cardona J;Mocherla B;Stosor V;Shawa I;Adams AC;Van Naarden J;Custer KL;Shen L;Durante M;Oakley G;Schade AE;Sabo J;Patel DR;Klekotka P;Skovronsky DM;BLAZE-1 Investigators
通讯作者:
BLAZE-1 Investigators
DOI:
10.4049/jimmunol.2000583
发表时间:
2020-08-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Alsoussi WB;Turner JS;Case JB;Zhao H;Schmitz AJ;Zhou JQ;Chen RE;Lei T;Rizk AA;McIntire KM;Winkler ES;Fox JM;Kafai NM;Thackray LB;Hassan AO;Amanat F;Krammer F;Watson CT;Kleinstein SH;Fremont DH;Diamond MS;Ellebedy AH
通讯作者:
Ellebedy AH
影响因子:
30.3
作者:
Case, James Brett;Rothlauf, Paul W.;Whelan, Sean P. J.
通讯作者:
Whelan, Sean P. J.
DOI:
10.1126/science.abe2402
发表时间:
2020-11-27
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Baum A;Ajithdoss D;Copin R;Zhou A;Lanza K;Negron N;Ni M;Wei Y;Mohammadi K;Musser B;Atwal GS;Oyejide A;Goez-Gazi Y;Dutton J;Clemmons E;Staples HM;Bartley C;Klaffke B;Alfson K;Gazi M;Gonzalez O;Dick E Jr;Carrion R Jr;Pessaint L;Porto M;Cook A;Brown R;Ali V;Greenhouse J;Taylor T;Andersen H;Lewis MG;Stahl N;Murphy AJ;Yancopoulos GD;Kyratsous CA
通讯作者:
Kyratsous CA
影响因子:
48
作者:
Bepler, Tristan;Morin, Andrew;Berger, Bonnie
通讯作者:
Berger, Bonnie